Baker Bros. Advisors LP Rigel Pharmaceuticals Inc Transaction History

Baker Bros. Advisors LP

  • $9.34 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018
SELL
$2.6 - $3.59 $2.71 Million - $3.74 Million
-1,041,612 Closed
0 $0
Q2 2018

Aug 14, 2018
SELL
$2.83 - $4.11 $4.18 Million - $6.07 Million
-1,477,270 Reduced 58.65%
1,041,612 $2.95 Million
Q3 2017

Nov 14, 2017
BUY
$2.18 - $2.57 $5.49 Million - $6.47 Million
2,518,882
2,518,882 $6.4 Million

Others Institutions Holding RIGL

# of Institutions
9
Shares Held
334K
Call Options Held
0
Put Options Held
0
View Full List

About RIGEL PHARMACEUTICALS INC

RIGL Quotes by TradingView
  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.81B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email